HealthcareLarge capRs 45,625 crRs 31.3 cr traded a dayPharmaceuticals
Close on 2026-08-21
3,639.80
−0.51%
52-week range94% of the way up
2,388.403,718.20
Market cap
45,625 cr
P/E (TTM)
40.2×
industry 44×
EPS (TTM)
90.54
Revenue YoY
+24.8%
Q1 FY27
Profit YoY
+30.9%
Net margin
20.6%
+1.0pt vs a year ago
Growth trend
+3.4pt
vs last quarter’s YoY
1 month
+5.8%
Below 52w high
2.2%
RSI (14)
64
Daily swing
2.6%
average true range
Volume
0.5×
vs 20-day average
Traded
Rs 31 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
−0.90%
1 month
+5.81%
3 months
+17.52%
6 months
+22.19%
1 year
+46.77%
The read
written from the numbers on this page
The evidence leans constructive8 supporting, 1 against, 0 worth knowing
Supporting
trading 22% above its 200-day average
sitting at 94% of its 52-week range, with little overhead supply from trapped buyers
up 47% over twelve months
matches closing in on a 52-week high, which has beaten the market by +0.51 points over 20 sessions across 27,282 past signals
2 of the scans it matches have a positive measured record
6 independent kinds of evidence agree today, which is uncommon
revenue grew 25% year on year in the quarter ending 2026-06-30
net margin has widened from 19.2% to 20.6% across four quarters
Against
1 of the scans it matches has historically underperformed the market
Worth knowing
nothing the data supports either way
AJANTPHARM sits in Pharmaceuticals — worth checking whether the whole group is moving together or whether this name is doing it alone.
What would change this read: a close below 2,980, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working3
Profit rose year on year in all 4 of the last 4 quarters.
4
Net profit +30.9% year on year, Rs 255 cr to Rs 334 cr.
+30.9%Rs 255 crRs 334 cr
Revenue +24.8% year on year, Rs 1,303 cr to Rs 1,626 cr.
+24.8%Rs 1,303 crRs 1,626 cr
Needs watching
Nothing in the filings stands out either way.
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.
How it has performed
price return over each window, measured against zero
What the scans say today
8 of 47 matched on 2026-08-21
AJANTPHARM matches 8 of the 47 scans today, across 6 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
AJANTPHARM trades at 40× trailing earnings, above its median of 36× over this window — 11% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
M&A filings were typically +0.23pt vs the market over the next 5 sessions (n=981) · Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093) · Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 25% against the same quarter a year earlier
profit rose 31% year on year
net margin widened from 18.8% to 20.6%
revenue rose in 4 of the last 4 quarters
Going against it
nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
1,626
447
334
26.75
20.6%
Q4 FY26
2026-03-31 · consolidated
1,422
347
267
21.35
18.8%
Q3 FY26
2025-12-31 · consolidated
1,375
359
274
21.91
19.9%
Q2 FY26
2025-09-30 · consolidated
1,354
341
260
20.83
19.2%
Q1 FY26
2025-06-30 · consolidated
1,303
331
255
20.44
19.6%
Q4 FY25
2025-03-31 · consolidated
1,170
269
225
18.00
19.2%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+7.1%
Versus 200-day average+22.1%
Below 52-week high-2.1%
Above 52-week low+52.4%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)63.7
Higher closes in last 51 of 5
Six-month return+22.19%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)2.55%
Volume versus 20-day0.5x
Median daily turnoverRs 31.3 cr
Peers
Healthcare · 67 classified companies
AJANTPHARM trades at 40.2× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — priced roughly in line with them. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.